Solanezumab is a drug that binds soluble amyloid and helps clear this from the brain. This helps prevent the amyloid from going on to build brain plaques. The hope is this will halt the Alzheimer's disease progression, preserve thinking, and memory skills. This helps stall the mental decline and maintain greater cognitive function.
The National Institutes of Health and others will monitor amyloid levels and record cognitive test results with study participants. About half of the 2100 participants will receive 400 milligrams of Solanezumab per IV injection every month for 18 months.
The A4 Study is anti-amyloid treatment in asymptomatic Alzheimer's. Solanezumab is owned by Eli Lilly and Company. Participants are healthy seniors age 65 to 85 years of age. This is an attempt to divert the ingredients needed to assemble the development of Alzheimer's Disease, and stop the manifestation of undesired symptoms like memory loss.
The staff at Home Care Path hope Solanezumab study produces a favorable results. Thank you for your effort.
Home Care Path celebrates 4 years of successfully serving seniors in South Central Wisconsin
Web site www.homecarepath.com
Twitter https://twitter.com/seniorcareWI
App http://appsmakerstore.com/appim/j6kcdet8xvwk4s
Blog http://homecarepathseniorcare.blogspot.com/
Home Care Path www.homecarepath.com and the Wisconsin PATH ALONG model deliver an advanced supportive care service. Helping seniors in the home, with clinic visits, at the hospital, nursing home and assisted living facility. Helping seniors downsize with a move in to an adult child's home. 2014 rates are 20.00 per hour. Simply call 608-432-4286 to schedule an interview. We can be there when you are working. We accept long term care insurance. Services can be tax deductible. Help with resources and the transition from private payment to public funded programming. Valuing home and human life
No comments:
Post a Comment